Plain-English translation of NCT03608631 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage clinical trial testing mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes), a new treatment designed for people with advanced pancreatic cancer that has a specific genetic mutation called KRAS G12D. The medication works by delivering genetic instructions into cancer cells to block a mutation that helps tumors grow. Researchers want to find the right dose and learn whether this treatment can help control the disease.
Pancreatic cancer is very difficult to treat, especially when it has spread to other parts of the body. Many patients have a specific genetic mutation (KRAS G12D) that drives their cancer, but current treatments don't directly target this mutation. This trial explores whether the medication can attack cancer cells at the genetic level.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication over 15–20 minutes on days 1, 4, and 10 of each 2-week cycle, with the option to continue for up to 6 cycles total (about 12 weeks) if your cancer responds well. During treatment, you'll have regular blood tests and imaging scans to monitor how your cancer is responding and to watch for any side effects. After treatment ends, you'll have follow-up visits at 30 days and then every 3 months for up to 1 year.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States